权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Seeding and Continuous Biopharmaceutical Crystallisation (SCoBiC)

接种和连续生物药物结晶 (SCoBiC)

基本信息

批准号：
EP/N015916/1
负责人：
Jerry Heng
金额：
$ 129.44万
依托单位：
Imperial College London
依托单位国家：
英国
项目类别：
Fellowship
财政年份：
2016
资助国家：
英国
起止时间：
2016 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=EP%2FN015916%2F1
关键词：
Seeding Continuous Biopharmaceutical Crystallisation SCoBiC

项目摘要

Biotechnology has made significant advancements in the understanding of human genomics and proteomics revolutionising medical diagnosis, prevention and treatment. Advances and breakthroughs in target-oriented biotechnology research have been used to enhance the synthesis of a number of commercially significant products. It has been reported that there are over 6000 biopharmaceuticals currently in development, potentially worth in excess of $100's bn (£145bn in 2012). Despite the increasing successes in discovering protein-based medicines, their manufacture in a cost effective and reliable fashion remains a major industrial challenge, which currently limits the ability of the biopharmaceutical industry to deliver solutions to patients. The vision here is to develop a programme for process intensification and de-bottleneck of downstream bioprocessing (DSB), by implementation of Seeding and Continuous Biopharmaceutical Crystallisation (SCoBiC), for the separation and purification of biopharmaceuticals. The ambition of this proposed project to develop strategies for a continuous biocrystallisation process, including selective crystallisation directly from multicomponent fermentation broths by seeding, for whole antibodies and antibody fragments. The goal is to reduce manufacturing costs, provide for simpler processes while achieving the high purity of material achievable from multi step chromatography. This ambition is driven by the awareness that separation and purification processes represent one of the most time and cost-intense downstream operations in the manufacture of commercial biopharmaceutical products. This proposal will develop a continuous biocrystallisation platform as an alternative to conventional DSB, offering improvements to manufacturability, enabling higher throughput, lowering the product costs, an increase in product quality and stability, including opportunities for novel formulations and technologies.

生物技术在理解人类基因组学和蛋白质组学方面取得了重大进展，彻底改变了医学诊断、预防和治疗。以目标为导向的生物技术研究的进展和突破已被用于加强一些具有商业意义的产品的合成。据报道，目前有超过6000种生物制药正在开发中，潜在价值超过1000亿美元（2012年为1450亿英镑）。尽管在发现基于蛋白质的药物方面取得了越来越多的成功，但以具有成本效益和可靠的方式制造蛋白质药物仍然是一个主要的工业挑战，这限制了生物制药行业为患者提供解决方案的能力。这里的愿景是通过实施播种和连续生物制药结晶（SCoBiC），为生物制药的分离和纯化制定一个过程强化和下游生物加工（DSB）的去瓶颈计划。该项目的目标是开发连续生物结晶过程的策略，包括通过播种直接从多组分发酵液中选择性结晶，用于整个抗体和抗体片段。目的是降低制造成本，提供更简单的工艺，同时实现多步色谱法可实现的高纯度材料。这一雄心壮志是由于人们意识到分离和纯化过程是商业生物制药产品制造中最耗时和成本最高的下游操作之一。该提案将开发一个连续的生物结晶平台，作为传统DSB的替代方案，提供可制造性的改进，实现更高的吞吐量，降低产品成本，提高产品质量和稳定性，包括新配方和技术的机会。

项目成果

期刊论文数量（10）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Crystal regeneration - a unique growth phenomenon observed in organic crystals post breakage.

晶体再生——在有机晶体破裂后观察到的一种独特的生长现象。

DOI：
10.1039/d2mh01180h
发表时间：
2023
期刊：
Materials horizons
影响因子：
13.3
作者：
Bade I
通讯作者：
Bade I

Protein crystal occurrence domains in selective protein crystallisation for bio-separation

用于生物分离的选择性蛋白质结晶中的蛋白质晶体出现域

DOI：
10.1039/d0ce00642d
发表时间：
2020
期刊：
CrystEngComm
影响因子：
3.1
作者：
Li X
通讯作者：
Li X

The Effect of Chain Length and Conformation on the Nucleation of Glycine Homopeptides during the Crystallization Process.

DOI：
10.1021/acs.cgd.2c01229
发表时间：
2023-03-01
期刊：
CRYSTAL GROWTH & DESIGN
影响因子：
3.8
作者：
Guo, Mingxia;Jones, Marie J.;Goh, Racheal;Verma, Vivek;Guinn, Emily;Heng, Jerry Y. Y.
通讯作者：
Heng, Jerry Y. Y.

Surface hydrophobicity: effect of alkyl chain length and network homogeneity